Turan, NedimBenekli, MustafaUnal, Olcun UmitUnek, Ilkay TugbaTastekin, DidemDane, FaysalAlgin, Efnan2024-04-242024-04-2420151000-96041993-0631https://doi.org/10.3978/j.issn.1000-9604.2015.08.03https://hdl.handle.net/11468/19443Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013. Results: Of 563 patients, 472 received adjuvant chemotherapy (CT) alone, chemoradiotherapy (CRT) alone, and chemoradiotherapy plus chemotherapy (CRT-CT) were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival (RFS) and overall survival (OS) were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant difference between groups when patients with node-negative disease or patients with or without positive surgical margins were considered. Conclusions: Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection.eninfo:eu-repo/semantics/closedAccessPancreatic AdenocarcinomaAdjuvant Chemotherapy (Adjuvant Ct)Adjuvant RadiotherapyArticle274408416WOS:0003609409000102-s2.0-849405533862636141010.3978/j.issn.1000-9604.2015.08.03N/AQ3